PrimeBioMed Overview
- Founded
- 2013
- Status
- Private
- Employees
- 5
- Latest Deal Type
- Early Stage VC
- Investors
- 2
PrimeBioMed General Information
Description
Developer of molecular-cell diagnostic technology intended to develop antibodies for cancer diagnosis. The company's technology uses recombinant diagnosis and long-established hybridoma lines for the development of antibodies, enabling the healthcare industry to treat cancer easily.
Contact Information
Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
- Nauchny pr. 20, p. 3
- Moscow, 117246
- Russia
+7 8 (000) 000-00-00
PrimeBioMed Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Early Stage VC | 25-Sep-2017 | 00.000 | Completed | Generating Revenue | ||
| 2. Early Stage VC | 00.000 | Completed | Startup | |||
| 1. Early Stage VC (Series A) | 01-Jan-2013 | $2.02M | $2.02M | Completed | Startup |
PrimeBioMed Executive Team (3)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Alexey Grachev Ph.D | Co-Founder, General Director & Chief Executive Officer | ||
| Juliya Kzhyshkovska | Co-Founder | ||
| Olga Lopaeva | Co-Founder |
PrimeBioMed Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %ile
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialPrimeBioMed Investors (2)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Russian Venture Company | Venture Capital | Majority | 000 0000 | 000000 0 | |
| Skolkovo Foundation | Limited Partner | Minority | 000 0000 | 000000 0 |